Dr. Hudalla’s research creates functional biomaterials for therapeutic or diagnostic applications via molecular self-assembly. The Hudalla laboratory develops synthetic peptides that can assemble into a desired nano-scale architecture, and then uses these peptides as “tags” to organize biologically active molecules into functional nanomaterials. For example, their work has led to glycosylated nanofibers that inhibit the immunomodulatory activity of galectins, a family of carbohydrate-binding proteins. In another project, they combine enzymes and carbohydrate-binding proteins into catalytic nanomedicines that are anchored to tissues at an injection site via binding to extracellular carbohydrates. Hudalla’s long-term goals are to create biomaterials that can modulate immune responses for the treatment of autoimmune diseases and aberrant inflammation.